ロード中...
Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts
c‐MYC controls more than 15% of genes responsible for proliferation, differentiation, and cellular metabolism in pancreatic as well as other cancers making this transcription factor a prime target for treating patients. The transcriptome of 55 patient‐derived xenografts show that 30% of them share a...
保存先:
出版年: | EMBO Mol Med |
---|---|
主要な著者: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
フォーマット: | Artigo |
言語: | Inglês |
出版事項: |
John Wiley and Sons Inc.
2017
|
主題: | |
オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5376755/ https://ncbi.nlm.nih.gov/pubmed/28275007 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201606975 |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|